BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8619590)

  • 21. In vitro activity of OPC-17116.
    Neu HC; Fang W; Gu JW; Chin NX
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA; Jones RN
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.
    Eliopoulos GM; Klimm K; Rice LB; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1154-9. PubMed ID: 2393275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
    Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
    Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
    Sader HS; Erwin ME; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):372-81. PubMed ID: 1327789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
    Bremm KD; Petersen U; Metzger KG; Endermann R
    Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
    Barrett MS; Jones RN; Erwin ME
    Eur J Clin Microbiol Infect Dis; 1993 Feb; 12(2):134-41. PubMed ID: 8388792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
    Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.